Login
$ACH
$0.09 +$0.00 (0.0%) After hours

$ACH SEC Filings

Filed On Filing
16 Nov 2026 144
12 Nov 2026 SCHEDULE 13G
06 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuin...

04 Nov 2026 Form 3: Lloyd Scott MacRae, EVP, Chief Commercial Officer

No securities owned

03 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

1 October 29, 2026 Perry A. Bernocchi Delivered Via Email Re: Transition Agreement Dear Perry, This letter agreement (this “Agreement”) sets forth the terms of your transition from Executive Vice President, Chief Operating Officer (“COO”...

02 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Richmond, VA – November 2, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, ...

30 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure

Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity;

29 Oct 2026 DEF 14A
19 Oct 2026 PRE 14A
09 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure

RICHMOND, VA – October 9, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is ...

07 Oct 2026 SCHEDULE 13G
06 Oct 2026 Form 4: Gardner-Smith Kenneth, Director

Received 283,554 shares as a grant or award

28 Sep 2026 8-K/A: Departure/Election of Directors or Officers; Compensation

This letter agreement (this “Agreement”) sets forth the terms and conditions of the independent contractor relationship between Edward A. Pesicka (“Pesicka”) and Accendra Health, Inc. (the “Company”).

24 Sep 2026 Form 4: Leon Jonathan A, EVP & CFO

Gave up 4,265 shares to cover exercise price or tax ($3.63K)

17 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

11 Sep 2026 144
17 Aug 2026 8-K: Regulation FD Disclosure

RICHMOND, VA – August 17, 2026 – Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer.

10 Aug 2026 8-A12B
10 Aug 2026 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more

This Section 382 Rights Agreement (this “Agreement”), dated as of August 10, 2026, is between Accendra Health, Inc., a Virginia corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as r...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support